Skip to content

EXOZ EXOZ Lease Liability Payments - Remainder of Fiscal Year

Lease Liability Payments - Remainder of Fiscal Year at other companies

NAG
Niagen Bioscience, Inc. Common StockNAGE
$782K-33.9%
Upexi logo
UpexiUPXI
$128.22K-83.3%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$17.5K
Operating income-$2.4M-22.4%
Net income-$2.4M-27.7%
EPS (diluted)-$0.28-27.3%

Balance sheet

See full
Cash & equivalents$1.4M-83.0%
Total debt$1.2M-8.8%
Total equity$1.5M-82.8%
Total assets$4.0M-65.1%

Cash flow

See full
Operating cash flow-$1.5M-34.5%
CapEx$57.6K+85.5%
Free cash flow-$1.6M-35.8%

Valuation

See full
Market cap$76.8M-5.6%
Enterprise value$76.57M+1.0%
P/S1,096.1×

Profitability

See full
Operating margin-14,489.6%
Net margin-2,909.1%
FCF margin-10,117.8%

Returns & leverage

See full
Return on equity-185.8%
Debt / equity0.8×+0.6×
Current ratio1.3×-5.2×

Where this comes from

Reported directly by EXOZ in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: EXOZ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about EXOZ's lease liability payments - remainder of fiscal year.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EXOZ's lease liability payments - remainder of fiscal year?
EXOZ (EXOZ) reported lease liability payments - remainder of fiscal year of $38.21K in Q1 2026.
How has EXOZ's lease liability payments - remainder of fiscal year changed year-over-year?
EXOZ's lease liability payments - remainder of fiscal year decreased by 89.3% year-over-year, from $358.43K to $38.21K.
What does lease liability payments - remainder of fiscal year mean?
The contractual cash obligations for operating and finance leases due within the remaining months of the current fiscal year. This provides a short-term view of the company's fixed lease commitments. It is a critical component for assessing near-term liquidity and cash flow requirements.